News

Article

Pharma Pulse 7/1/24: AI Frenzy Propels Stocks to Monster First Half, Considerations for Integrating Artificial Intelligence & more

Author(s):

Miranda Schmalfuhs

The latest news for pharma industry insiders.

Considerations for Integrating Artificial Intelligence

In part 4 of this video interview, Diane Lacroix, vice president, clinical data management, eClinical Solutions discusses what industry stakeholders should be keeping top of mind when integrating AI into their workflows.

Healthcare Takes Backseat in Biden-Trump Debate. Biden's Age Not So Much

The presidential candidates didn't spend a lot of time talking about healthcare issues last night, but Democrats are concerned about Biden's performance, especially in the early going.

AI Frenzy Propels Stocks to Monster First Half

S&P 500 has climbed 15% despite reduced hopes for Federal Reserve interest-rate cuts.

Global mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2024 - ResearchAndMarkets.com

The "Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.

Global mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2024 Report Highlights:

  • mRNA Cancer Vaccines in Clinical Trials: > 60 Vaccines
  • Highest Phase of Clinical Trials: Phase III (2 Vaccine)
  • mRNA Cancer Vaccine Clinical Trials Insight by Company, Country, Indication & Phase
  • First Commercial mRNA Vaccine Approval Expected by 2029
  • US & China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 Vaccines
  • mRNA Vaccines for Skin Cancer Dominating Trials: > 10 Vaccines

@ICONplc on X

The future of clinical research focuses on sustainability and patient-centricity. Discover key considerations for greener supply chain management in this piece from @Clin_Trials : https://ow.ly/oYMj50Sq0Ms

Have news you want us to share in Pharma Pulse? Reach out to Social

Media Editor Miranda Schmalfuhs

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Robert Lisicki
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Related Content
FDA Grants Priority Review to Bristol Myers Squibb’s Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma
August 5th 2025

FDA Grants Priority Review to Bristol Myers Squibb’s Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma

Don Tracy, Associate Editor
The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed that patients treated with Breyanzi for relapsed or refractory marginal zone lymphoma demonstrated strong and lasting responses.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 5th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Site Logo
August 5th 2025

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Karla Anderson, Partner, Guidehouse Jacob Graham, Partner, Guidehouse Cavay Ip, Director, Guidehouse
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 5th 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Harshit Jain, MD
August 5th 2025

From Scatter to Scale: Rethinking Marketing/Programmatic Strategy for Amplified HCP Reach and Engagement

Harshit Jain
One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation in reach and scalability they possess.
Spine BioPharma’s TGF-β Antagonist Misses Primary Endpoint in Phase III Degenerative Disc Disease Trial
August 5th 2025

Spine BioPharma’s TGF-β Antagonist Misses Primary Endpoint in Phase III Degenerative Disc Disease Trial

Don Tracy, Associate Editor
Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase III MODEL trial (NCT05516992), reinforcing its potential as a non-surgical treatment for chronic low back pain associated with degenerative disc disease.